Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2015-01-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.4088/JCP.13m08921PMID 25188033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Transporters on Arachnoid Barrier Cells Contribute to the Blood–Cerebrospinal Fluid Barrier

  2013cited by this paper
• Utility of CSF in translational neuroscience

  2013cited by this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cited by this paper
• Fluids and Barriers of the CNS: a new journal encompassing Cerebrospinal Fluid Research

  2011cited by this paper
• High Correlation Between Serum and Cerebrospinal Fluid Olanzapine Concentrations in Patients With Schizophrenia or Schizoaffective Disorder Medicating With Oral Olanzapine as the Only Antipsychotic Drug

  2011cited by this paper
• Doxepin concentrations in plasma and cerebrospinal fluid

  2011cited by this paper
• Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate

  2011cited by this paper
• Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

  2010cited by this paper
• Quetiapine and Norquetiapine in Plasma and Cerebrospinal Fluid of Schizophrenic Patients Treated With Quetiapine: Correlations to Clinical Outcome and HVA, 5-HIAA, and MHPG in CSF

  2010cited by this paper
• Unbound Drug Concentration in Brain Homogenate and Cerebral Spinal Fluid at Steady State as a Surrogate for Unbound Concentration in Brain Interstitial Fluid

  2009cited by this paper
• Drug targeting to the brain

  2008cited by this paper
• Increased blood-brain barrier permeability is not a primary determinant for lethality of West Nile virus infection in rodents.

  2008cited by this paper
• Barriers in the brain: a renaissance?

  2008cited by this paper
• Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy

  2008cited by this paper
• Mirtazapine Enantiomers in Blood and Cerebrospinal Fluid

  2007cited by this paper
• Comparison of Brain Extracellular Fluid, Brain Tissue, Cerebrospinal Fluid, and Serum Concentrations of Antiepileptic Drugs Measured Intraoperatively in Patients with Intractable Epilepsy

  2006cited by this paper
• CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

  2006cited by this paper
• Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response

  2005cited by this paper
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Potential role of ABC transporters as a detoxification system at the blood-CSF barrier.

  2004cited by this paper
• Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology.

  2004cited by this paper
• Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

  2004cited by this paper
• Stereoselective Metabolism of Citalopram in Plasma and Cerebrospinal Fluid of Depressive Patients: Relationship with 5-HIAA in CSF and Clinical Response

  2004cited by this paper
• Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

  2004cited by this paper
• Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.

  2003cited by this paper
• The human ATP-binding cassette (ABC) transporter superfamily.

  2001cited by this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cited by this paper
• Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.

  1999cited by this paper
• Venlafaxine. A review of its pharmacology and therapeutic potential in depression.

  1995cited by this paper
• Active Hydroxymetabolites of Antidepressants

  1995cited by this paper
• A High‐Performance Liquid Chromatographic Method for the Simultaneous Determination of Venlafaxine and O‐Desmethylvenlafaxine in Biological Fluids

  1994cited by this paper
• Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.

  1987cited by this paper
• Correlation between plasma and cerebrospinal levels of imipramine.

  1976cited by this paper

• Optimizing Venlafaxine Therapy in Pregnancy: A Maternal–Fetal PBPK Modeling Approach

  2025cites this paper
• Developing a machine learning model for predicting venlafaxine active moiety concentration: a retrospective study using real-world evidence

  2024cites this paper
• Personalized, Precision Medicine to Cure Alzheimer’s Dementia: Approach #1

  2024cites this paper
• Venlafaxine’s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis

  2023cites this paper
• Modulation of microglial activation by antidepressants

  2022cites this paper
• Pregnancy exposure to venlafaxine-Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes.

  2020cites this paper
• Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis

  2020influential citation
• Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine

  2020cites this paper
• Pharmakotherapie bipolarer Störungen in Schwangerschaft und Stillzeit

  2019cites this paper
• Mit „Therapeutischem Drug Monitoring“ Psychopharmakotherapie optimieren

  2018cites this paper
• Effect of human pharmaceuticals common to aquatic environments on hepatic CYP1A and CYP3A-like activities in rainbow trout (Oncorhynchus mykiss): An in vitro study.

  2018cites this paper
• Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates

  2018cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2018cites this paper
• Pregnancy exposure to citalopram - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood.

  2017cites this paper
• Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

  2017cites this paper
• Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants

  2016cites this paper
• Current advances in biosampling for therapeutic drug monitoring of psychiatric CNS drugs.

  2015cites this paper
• Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid.

  2015cites this paper
• Distribution pattern of mirtazapine and normirtazapine in blood and CSF

  2015cites this paper
• Arzneimittelmetabolismus und Therapieversagen

  2015cites this paper